TPS CLIA has received approval for use on Fosun Diagnostics’ fully automated system in China
Our partner, ZECEN Biotech, has received the registration certificate from the Chinese registration authorities NMPA. This means that TPS CLIA is now also approved for use on Fosun Diagnostics' fully automated CLIA platforms in China.
“We are happy that this product is approved and ready to be launched on the Chinese market. The expansion of TPS on different platforms will result in a broader reach and increased presence on the market. We are looking forward to continuing our collaboration with ZECEN Biotech, and expanding collaboration into other tumor markers on their machines in the future” says Marie Torstensson, Chief Market and Sales Officer Laboratory Test.
About ZECEN Biotech
ZECEN Biotech Co., Ltd., is a Chinese company that mainly specializes in providing total chemiluminescence immunoassay solutions by developing, manufacturing, and marketing CLIA instruments and reagents. The company has research and development centers and a production base in Beijing, Shandong, and Jiangsu. ZECEN Biotech Co., Ltd., and cooperates with leading hospitals in China.
About Fosun Diagnostics
Fosun Diagnostics is a division within Shanghai Fosun Pharmaceutical (Group) Co Ltd, focusing on developing, manufacturing, and distributing in vitro diagnostics (IVD) products.